StockData

Ensysce Biosciences vs Kyntra Bio

ENSC and KYNB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENSC and KYNB compare

Kyntra Bio is the larger company, worth 1.7 times as much as Ensysce Biosciences ($13.9M against $8.1M).

Ensysce Biosciences grew revenue faster over the last twelve months (37.9% versus −37.1% for Kyntra Bio).

Ensysce Biosciences scores higher on the StockData Score (9 against 5 for Kyntra Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENSCKYNB
Size and price
Market cap$8.1M$13.9M
Share price$0.418$3.44
Change, 1 year−79.7%−62.3%
Change, 5 years−100.0%−98.9%
Beta (5Y)2.591.24
Employees834
StockData Score
Total score9 (better)5
Valuation score3 (better)2
Growth score2 (better)0
Performance score02 (better)
Health score4 (better)1
Dividend score00
Valuation
P/E–0.1×
P/S1.3× (better)3.0×
P/B0.3×–
FCF yield–−273%
Fair value$1.73–
Margin of safety75.8%–
Growth
Revenue growth (TTM)37.9% (better)−37.1%
Revenue growth, 5Y average5.2% (better)−48.4%
Profitability
Gross margin–6.3%
Operating margin−1477%−1090% (better)
Net margin–3968%
FCF margin–−824%
Financial health
Debt / equity0.00–
Interest coverage−7157.6×−5.4× (better)
Current ratio8.02 (better)2.69
Altman Z-score−17.54 (better)−24.47
Piotroski F-score–5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions4.7%24.7%
Held by insiders6.2%15.7%
Insider net buying, 12 months$444K (better)$39.7K
Short interest, % of float0.49%2.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.